ALLMedicine™ Cholangiocarcinoma Center
Research & Reviews 4,834 results
https://doi.org/10.1530/ERC-22-0389
Endocrine-related Cancer; Guevara-Aguirre J, Peña G et. al.
Mar 28th, 2023 - 2018-2022 meta-analysis have shown that obesity increases the risk of various cancers such as acute myeloid lymphoma, chronic myeloid lymphoma, diffuse beta cell lymphoma, Hodgkin's lymphoma, leukemia, multiple myeloma, non-Hodgkin's lymphoma, bla...
https://doi.org/10.1007/s00432-023-04704-3
Journal of Cancer Research and Clinical Oncology; Jang YJ, Kim EJ et. al.
Mar 28th, 2023 - Immune checkpoint inhibitors (ICIs) have been demonstrated to be effective for unresectable or metastatic hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA) in prior prospective trials. However, the clinical outcomes of ICIs in patients wi...
https://doi.org/10.1245/s10434-023-13351-4
Annals of Surgical Oncology; Alaimo L, Moazzam Z et. al.
Mar 26th, 2023 - ASO Author Reflections: Long-Term Outcomes and Optimal Margin Width Among Patients Undergoing Hepatectomy for Intrahepatic Cholangiocarcinoma.|2023|Alaimo L,Moazzam Z,Pawlik TM,|
https://doi.org/10.1097/MPG.0000000000003781
Journal of Pediatric Gastroenterology and Nutrition; Malham M, Jansson S et. al.
Mar 25th, 2023 - Paediatric-onset inflammatory bowel disease (pIBD) increases the risk of developing several different cancer forms. In this case-control study, we aimed to assess the impact of medical treatment and disease activity on the risk of developing disea...
https://doi.org/10.1093/oncolo/oyad005
The Oncologist; Stenzinger A, Cuffel B et. al.
Mar 25th, 2023 - Adoption of high-throughput, gene panel-based, next-generation sequencing (NGS) into routine cancer care is widely supported, but hampered by concerns about cost. To inform policies regarding genomic testing strategies, we propose a simple metric,...
Guidelines 10 results
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.
Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.
May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.
Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.
Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...
https://doi.org/10.1200/JCO.18.02178
Journal of Clinical Oncology : Official Journal of the Am... Shroff RT, Kennedy EB et. al.
Mar 12th, 2019 - To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for ...
Drugs 4 results see all →
Clinicaltrials.gov 472 results
https://clinicaltrials.gov/ct2/show/NCT04507503
Mar 24th, 2023 - This is an open-label study to provide expanded access to TAS-120 prior to its commercial availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements who have failed standard therapy or who are unable to tolerate...
https://clinicaltrials.gov/ct2/show/NCT03412877
Mar 23rd, 2023 - Background: The administration of autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of participants with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique...
https://clinicaltrials.gov/ct2/show/NCT04565275
Mar 14th, 2023 - Part I (Phase I) of the study enrolls patients with advanced solid tumors (9-15 patients); Part II (Phase II) of the study enrolls patients with urothelial carcinoma or cholangiocarcinoma with FGFR genetic alterations (30 patients).
https://clinicaltrials.gov/ct2/show/NCT04989218
Mar 13th, 2023 - All enrolled participants will receive the study intervention. Patients will receive up to 4 cycles of interventional agents prior to surgical resection. They will undergo imaging scans after the 2nd and 4th cycle (before surgery) of intervention ...
https://clinicaltrials.gov/ct2/show/NCT04301011
Mar 10th, 2023 - This is a Phase 1/2a dose escalation study with TBio-6517 administered by direct injection into tumor(s) or by intravenous infusion. The Phase 1 portion has 4 arms; the first arm (Arm A) will determine the RP2D of TBio-6517 alone when directly inj...
News 461 results
https://www.mdedge.com/hematology-oncology/article/260788/understanding-cholangiocarcinoma-how-biomarker-testing-can-lead
Dr. Vaibhav Sahai, MD, MS
Feb 13th, 2023 - PEMAZYRE® (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected b.
https://www.mdedge.com/gihepnews/article/260476/pancreas-and-biliary-tract/genomics-data-reveal-promising-psc-therapeutic
Tara Haelle, MDedge News
Jan 4th, 2023 - An investigation of genomics data related to primary sclerosing cholangitis (PSC) in published medical literature revealed several genes likely involved in the pathogenesis of this autoimmune diseases, according to a study published in Gastro Hep.
https://www.onclive.com/view/fgfr2-inhibitor-rly-4008-appears-durable-tolerable-in-cholangiocarcinoma
Nov 23rd, 2022 - RLY-4008, a highly selective FGFR2 inhibitor, has demonstrated promising efficacy in patients with FGFR2-altered cholangiocarcinoma, while sparing patients the adverse effects (AEs) typically seen with pan-FGFR inhibitors, according to Suneel Kama...
https://www.onclive.com/view/tumor-profiling-studies-illuminate-nuances-across-malignancies
Nov 21st, 2022 - Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods (NGS) are taken up in clinical practice. Posters presented at the European Soc...
https://www.medscape.com/viewarticle/983968
Nov 12th, 2022 - Untreated chronic hepatitis B infections are associated with increased risks of most major extrahepatic cancer types, shows a new study conducted in South Korea. In this study, which was published in the Journal of Clinical Oncology, researchers f...